Literature DB >> 25923953

PREDICTIVE VALUE OF TNM CLASSIFICATION, INTERNATIONAL CLASSIFICATION, AND REESE-ELLSWORTH STAGING OF RETINOBLASTOMA FOR THE LIKELIHOOD OF HIGH-RISK PATHOLOGIC FEATURES.

Yacoub A Yousef1, Maysa Al-Hussaini, Mustafa Mehyar, Iyad Sultan, Imad Jaradat, Khaleel AlRawashdeh, Samer Khurma, Rasha Deebajah, Ibrahim Nawaiseh.   

Abstract

PURPOSE: To evaluate the predictive value of the seventh edition American Joint Committee on Cancer (AJCC/UICC) TNM classification, the International Classification of Retinoblastoma (ICRB), and Reese-Ellsworth staging for retinoblastoma for the likelihood of high-risk pathologic features.
METHODS: A retrospective study of 50 primarily enucleated eyes from 49 retinoblastoma patients. Main outcome measures included demographics, TNM stage, ICRB group, Reese-Ellsworth stage, choroid, optic nerve, and anterior chamber invasion.
RESULTS: The median age at enucleation was 30 months. High-risk pathologic features mandating adjuvant chemotherapy were seen in 5 of T2 eyes (22%), in 15 of T3 eyes (56%) (P = 0.021), in 1 of ICRB Group C eyes (13%), 8 of Group D eyes (33%), and 11 of Group E eyes (61%) (P = 0.035). High-risk pathologic features were 4.61 and 3.68 times more likely to be diagnosed at a more advanced T stage and ICRB group consecutively, whereas 0.133 time less likely to be diagnosed at a more advanced Reese-Ellsworth stage. At median follow-up of 40 months, no single case had metastasis or was dead.
CONCLUSION: The higher tumor clinical TNM stage and the more advanced ICRB group at presentation are associated with higher frequency of high-risk pathologic features and may predict which patients should receive adjuvant chemotherapy.

Entities:  

Mesh:

Year:  2015        PMID: 25923953     DOI: 10.1097/IAE.0000000000000547

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  4 in total

Review 1.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

2.  The Predictive Value of the Eighth Edition of the Clinical TNM Staging System for the Likelihood of Eye Salvage for Intraocular Retinoblastoma by Systemic Chemotherapy and Focal Therapy.

Authors:  Yacoub A Yousef; Mona Mohammad; Mustafa Mehyar; Iyad Sultan; Maysa Al-Hussaini; Joud Alhourani; Hadeel Halalsheh; Jakub Khzouz; Imad Jaradat; Ibrahim Qaddoumi; Ibrahim Al-Nawaiseh
Journal:  J Pediatr Hematol Oncol       Date:  2021-08-01       Impact factor: 1.170

3.  Management outcome(s) in eyes with retinoblastoma previously inadequately treated with systemic chemotherapy alone without focal therapy.

Authors:  Yacoub A Yousef; Rashed M Nazzal; Mohammed B Khalil; Rasha Deebajah; Mustafa Mehyar; Shatha Hajja; Mona Mohammad; Reem Al Jabary; Imad Jaradat; Iyad Sultan; Ibrahim Al Nawaiseh
Journal:  Oman J Ophthalmol       Date:  2017 May-Aug

4.  A Proposal for Future Modifications on Clinical TNM Staging System of Retinoblastoma Based on the American Joint Committee on Cancer Staging Manual, 7th and 8th Editions.

Authors:  Yacoub A Yousef; Ibrahim Qaddoumi; Ibrahim Al-Nawaiseh; Mona Mohammad; Dalia AlRimawi; Mario Damiano Toro; Sandrine Zweifel; Robert Rejdak; Rashed Nazzal; Mustafa Mehyar; Imad Jaradat; Iyad Sultan; Maysa Al-Hussaini
Journal:  J Cancer       Date:  2022-02-07       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.